Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Blinks, But Is $93 Enough For Genentech Shareholders?

Executive Summary

Is $93 the magic number

You may also be interested in...



Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

Blinding Them With Science: Genentech Tries To Win Shareholders Over

Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked

The Genentech Sales Pitch: Higher Values R Us

Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel